Epigenomics appeals recent FDA request for additional information

Company believes that an approval for the intended use of Epi proColon is warranted based on the data that has been submitted to date.
Epigenomics has announced that after discussions with FDA in relation to its premarket approval (PMA) application for the company's blood-based colorectal cancer (CRC) screening test Epi proColon, it is appealing the agency's decision on additional data requirements. Epigenomics is requesting a supervisory review of the recent decision to require additional clinical data to support PMA approval.
Epigenomics believes that an approval for the intended use of Epi proColon is warranted based on the data that has been submitted to date. The company has provided an extensive amount of data under its PMA application and received a favorable recommendation by the FDA Medical Device Advisory Committee in March 2014. Furthermore, in its appeal, Epigenomics has highlighted the difficulties to measure adherence in the intended use population under the existing regulatory framework along with a willingness to work with FDA to design an appropriate post-approval study.
FDA regulations provide several mechanisms to applicants for further review of the agency's actions. A request for supervisory review is directed to the next organizational level above the level at which the decision was made. Based on respective guidelines and following discussions with FDA, Epigenomics believes the supervisory review will be completed in Q1 2016.
Any decision on the company's appeal does not affect to the right of Epigenomics to amend its PMA application in the future.
"We are convinced that our appeal is well substantiated and in the best interest of patients, healthcare professionals and our shareholders," said Dr Thomas Taapken, CEO of Epigenomics. "While it is proven that screening and early detection of colorectal cancer can save lives, still one out of three eligible US citizens does not undergo colorectal cancer screening. Epi proColon(R) will allow those patients to make a healthcare choice that may benefit early detection and treatment of colorectal cancer. We are committed to continuing to work closely and collaboratively with FDA reviewers and supervisory staff through the process."
Related News
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ... -
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
-
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi.
-
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available.
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance